Genexine, Inc. (KOSDAQ:095700)
South Korea
· Delayed Price · Currency is KRW 4,860.00
-220.00 (-4.33%)
At close: Mar 9, 2026
Genexine Revenue
Genexine had revenue of 2.07B KRW in the quarter ending March 31, 2024, with 199.63% growth. This brings the company's revenue in the last twelve months to 5.81B, down -3.50% year-over-year. In the year 2023, Genexine had annual revenue of 4.43B, down -72.57%.
Revenue (ttm)
5.81B
Revenue Growth
-3.50%
P/S Ratio
38.06
Revenue / Employee
67.53M
Employees
86
Market Cap
221.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 4.43B | -11.71B | -72.57% |
| Dec 31, 2022 | 16.14B | -20.69B | -56.18% |
| Dec 31, 2021 | 36.83B | 18.28B | 98.61% |
| Dec 31, 2020 | 18.54B | 7.24B | 64.06% |
| Dec 31, 2019 | 11.30B | 5.05B | 80.80% |
| Dec 31, 2012 | Pro | Pro | Pro |
| Dec 31, 2011 | Pro | Pro | Pro |
| Dec 31, 2010 | Pro | Pro | Pro |
| Dec 31, 2009 | Pro | Pro | Pro |
| Dec 31, 2008 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EASY BIO,Inc. | 465.24B |
| HLB Therapeutics | 63.25B |
| iNtRON Biotechnology | 5.56B |
| Vaxcell-Bio Therapeutics | 1.90B |
| Macrogen | 179.98B |
| ENCell | 5.91B |
| Helixmith | 3.74B |
| JETEMA, | 75.55B |